ClinicalTrials.gg
RecruitingNCT07536516DM OPF ROXYUpdated Apr 17, 2026

Measurement of Ocular Blood Flow and Retinal Oxygen Extraction in Diabetic Patients

An interventional study of • Laser Speckle Flowgraphy (LSFG) and • Optical Coherence Tomography (OCT) in Diabetes Mellitus, sponsored by Medical University of Vienna. Recruiting at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by Medical University of Vienna · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Diabetes Mellitus by Medical University of Vienna — 1 open to participants now, 1 under way, none of them phase 3. Diabetes Mellitus · Medical University of Vienna.

Planned enrollment
4th of 10
20 · median 18
Started
2025
the only one that year
No phase
5 of 13
1 open now
Registered
13th of 13
by date

Among the 13 studies in Diabetes Mellitus by Medical University of Vienna, this one is the 4th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2025, is one of 5 with no phase, and was the 13th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

1 of the 13 studies in Diabetes Mellitus by Medical University of Vienna is open now, in 1 country.

By country, each count listing its studies:

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Diabetes Mellitus by Medical University of Vienna, or all of them as a file.
02

Study summary

The prevalence of diabetes is increasing, with type 2 diabetes mellitus comprising over 90% of cases. Diabetes mellitus complications, including diabetic retinopathy (DR), impose significant health burdens. GLP-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1 receptor agonists show promise in improving cardiovascular and kidney outcomes, but their effects on retinal microvasculature and neuroprotection remain unclear. This study investigates the impact of GLP-1RAs (semaglutide, liraglutide) and GIP/GLP-1-dual agonists (tirzepatide) on ocular blood flow and retinal function in DM patients.

03

Conditions studied

  • Diabetes Mellitus

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged ≥ 18 years
  • Signed
  • Previously diagnosed diabetes mellitus
  • Normal ophthalmic findings except diabetic retinopathy, unless the investigator considers an abnormality to be clinically irrelevant
  • Planned initiation of therapy with GLP-1 receptor agonist (Semaglutide, Ozempic®; Liraglutide, Victoza®) or GIP/GLP-1 receptor agonist (Tirzepatide, Mounjaro®) by a diabetes specialist

Exclusion criteria

Exclusion Criteria:

  • Participation in a clinical trial in the 3 weeks preceding the screening visit
  • Symptoms of a illness in the 3 weeks before the first study day
  • Presence or history of a severe medical condition, except diabetes, as judged by the clinical investigator
  • Abuse of alcoholic beverages
  • Blood donation during the previous three weeks
  • Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator
  • Previous laser photocoagulation treatment in the study eye
  • Best corrected visual acuity \< 0.4 Snellen
  • Women of (neither menopausal, nor hysterectomized, nor sterilized) not using effective
  • Pregnancy, planned pregnancy or lactation
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Diabetes mellitus GLP1-RA

    Measurements of the Ocular Blood Flow and Retinal Oxygen Extraction are performed.

    Device: • Laser Speckle Flowgraphy (LSFG) · Device: • Optical Coherence Tomography (OCT) · Device: • Optical Coherence Tomography Angiography (OCT-A)

Interventions

  • Device• Laser Speckle Flowgraphy (LSFG)

    Laser Speckle Flowgraphy (LSFG)

  • Device• Optical Coherence Tomography (OCT)

    • Optical Coherence Tomography (OCT)

  • Device• Optical Coherence Tomography Angiography (OCT-A)

    • Optical Coherence Tomography Angiography (OCT-A)

06

What researchers measure

Primary outcomes

  1. Ocular blood flow (LSFG)

    Ocular Blood Flow measured by Laser Speckle Flowgraphy (LSFG) in arbitrary units

    Time frame: From enrollment to last study day (=5-11 weeks)

Secondary outcomes

  1. Retinal vessel diameter

    Retinal vessel diameter with DVA

    Time frame: From enrollment to last study day (=5-11 weeks)

  2. Retinal oxygen saturation

    Retinal oxygen saturation with DVA

    Time frame: From enrollment to last study day (=5-11 weeks)

  3. Retinal oxygen extraction

    Retinal oxygen extraction will be calculated from measurements of ocular blood flow and retinal oxygen saturation. The calculation will be based on a formula integrating these parameters to estimate retinal oxygen extraction. Unit of Measure: Arbitrary units

    Time frame: From enrollment to last study day (=5-11 weeks)

  4. Oxygen and carbon dioxide partial pressure in arterialized blood

    Oxygen and carbon dioxide partial pressure in arterialized blood

    Time frame: From enrollment to last study day (=5-11 weeks)

  5. Central retinal thickness

    Central retinal thickness with OCT

    Time frame: From enrollment to last study day (=5-11 weeks)

  6. Retinal nerve fiber layer thickness

    Retinal nerve fiber layer thickness with OCT

    Time frame: From enrollment to last study day (=5-11 weeks)

  7. Retinal and choroidal microvasculature

    Retinal and choroidal microvasculature with OCT-A

    Time frame: From enrollment to last study day (=5-11 weeks)

  8. Capillary blood glucose level

    Capillary blood glucose level in mg/dL

    Time frame: From enrollment to last study day (=5-11 weeks)

  9. Autonomic and sensomotoric neuropathy measurements

    Short-term spectral analysis of Heart rate variability (HRV) is obtained from recordings consisting of 256 seconds of artifact free recordings. Parameters of frequency-domain HRV are measured within the low-frequency band and high-frequency band, as well as total spectral variability. Outcome variables are spectral power (ms2) in both frequency bands as well as cumulative indices.

    Time frame: From enrollment to last study day (=5-11 weeks)

  10. Ocular perfusion pressure

    Ocular perfusion pressure is calculated from systemic blood pressure and intraocular pressure. Unit of measurement: mmHg

    Time frame: From enrollment to last study day (=5-11 weeks)

  11. Intraocular pressure

    Intraocular pressure

    Time frame: From enrollment to last study day (=5-11 weeks)

  12. Systemic hemodynamics - Blood pressure

    Systolic and diastolic blood pressure is measured. Unit: mmHg

    Time frame: From enrollment to last study day (=5-11 weeks)

  13. Schirmer I Test

    Schirmer I Test is performed. Unit of measuremnt: mm

    Time frame: From enrollment to last study day (=5-11 weeks)

  14. Finger sweat sampling

    Finger sweat samples will be collected using stamped-out filter paper applied to the fingertip under standardized conditions. Samples will be analyzed using an untargeted multi-omics approach. Proteomic, eicosadomic, and metabolomic profiles will be assessed using high-resolution mass spectrometry platforms. Unit of Measure: Arbitrary units (normalized intensity values)

    Time frame: From enrollment to last study day (=5-11 weeks)

  15. Systemic hemodynamics - Heart rate

    Heart rate is measured. Unit: Hz

    Time frame: From enrollment to last study day (=5-11 weeks)

  16. Systemic hemodynamics - Oxygen saturation

    Oxygen saturation is measured. Unit: %

    Time frame: From enrollment to last study day (=5-11 weeks)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for May 2026, 5 months after the start.

Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 5 months is below that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2025
First posted
Apr 17, 2026
StartActual
Nov 28, 2025
Primary completionEst.
May 1, 2026
CompletionEst.
Jun 1, 2026
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07536516
Responsible party
Doreen Schmidl (Assoc. Prof. Priv. Doz. Dr., PhD, Medical University of Vienna) — Principal investigator
First posted
Apr 17, 2026
Start date
Nov 28, 2025
Primary completion
May 1, 2026 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
Apr 17, 2026

Study contacts

Doreen Schmidl, Prof. Priv. Doz. MD.; PhD
Contact
doreen.schmidl@meduniwien.ac.at
+431404002981
Doreen Schmidl, Prof. Priv. Doz. MD, PhD
Contact
+431404002981

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion